Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837819 | 0.76 | AXL (0.48) | AXLKMT2APARP1AURKAGPR84 | |
| SCHEMBL1566406 | 0.72 | AXL (0.53) | AXLKMT2APARP1AURKAGPR84 | |
| SCHEMBL30421286 | 0.72 | AXL (0.53) | AXLKMT2APARP1AURKAGPR84 | |
| Quinazolinone SCHEMBL10418 | 0.71 | PARP1 (0.48) | KMT2APARP1AURKAGPR84LRRK2 | |
| Hydrochloric Acid SCHEMBL29744480 | 0.71 | AXL (0.52) | AXLKMT2APARP1AURKAGPR84 | |
| SCHEMBL29431626 | 0.70 | — | — | |
| SCHEMBL10759 | 0.70 | — | — | |
| Quinazolinone SCHEMBL7746268 | 0.69 | PARP1 (0.47) | KMT2APARP1AURKAGPR84LRRK2 | |
| SCHEMBL410624 | 0.69 | AXL (1.00) | AXLKMT2AGPR84LRRK2MAP2K1 | |
| SCHEMBL29655460 | 0.69 | AXL (1.00) | AXLKMT2AGPR84LRRK2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
| EP-0180834-B1 | 4-Alkoxypyrido[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-08-30 | — | — | EP | claimed |
| EP-0180833-B1 | 4-Oxo-pyrido-[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-07-19 | — | — | EP | claimed |
| US-12152051-B2 | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-11-26 | — | — | US | disclosed |
| US-20220274927-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-09-01 | — | — | US | disclosed |
| EP-3854799-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| EP-3544979-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| US-9957267-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9630962-B2 | 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | HOSPITAL CLINIC DE BARCELONA (ES) | 2017-04-25 | — | — | US | disclosed |
| EP-3008063-B1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) | 2017-04-19 | — | — | EP | disclosed |
| EP-0180833-B1 | 4-Oxo-pyrido-[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-07-19 | — | — | EP | disclosed |
| US-4762837-A | CARDIOVASCULAR DISORDERS | GODECKE AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| CN-85107634-B | process for producing 4-oxo-pyrido (2,3-d) pyrimidine derivative | 歌德克股份公司 | 1988-07-06 | — | — | CN | disclosed |
| US-4681882-A | TREATMENT OF VASCULAR DISEASES | GODECKE AKTIENGESELLSCHAFT (DE) | 1987-07-21 | — | — | US | disclosed |
| US-4677108-A | CARDIOVASCULAR DISEASES | WARNER-LAMBERT COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| US-4677108-A | CARDIOVASCULAR DISEASES | WARNER-LAMBERT COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0180833-A1 | 4-Oxo-pyrido-[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180834-A1 | 4-Alkoxypyrido[2,3-d]pyrimidine derivatives, process for their preparation and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1986-05-14 | — | — | EP | disclosed |
| US-4009166-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, CNS DEPRESSANTS | HISAMITSU PHARMACEUTICAL CO., INC. (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152051-B2 | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application | STING1, CGAS, IRF3 | AXL 3907/4885KMT2A 3533/4885PARP1 636/4885 |
| US-20220274927-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | LPO, EPCAM, ANTXR2 | AXL 2951/4885KMT2A 3062/4885PARP1 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.